Mederi Therapeutics launches 3rd generation of Stretta, Boston Scientific reports Q1 2016 financials & more — 5 GI company key notes

Here are five recent news updates on key gastroenterology and endoscopy companies.

Mederi Therapeutics launched of RFT3, the third generation of Stretta technology.

Boston Scientific reported 2016 first quarter sales of $1.96 billion. Additionally, Michael Phalen, acting executive vice president and president-MedSurg of Boston Scientific, recently sold 35,000 shares of the firm.

Galmed Pharmaceuticals in New York signed an investigator-initiated clinical trial agreement with the Icahn School of Medicine at Mount Sinai in New York to evaluate the effect of aramchol in combination with vitamin D for treatment of nonalcoholic fatty liver disease.

Tobira Therapeutics announced results from a 12-week interim analysis of the Phase 2a ORION study, which showed treatment with its drug, cenicriviroc, was well tolerated and associated with improvements in insulin sensitivity.

EndoChoice appointed William Enquist as chairman of the board of directors.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast